Prelude Therapeutics (PRLD) Assets (2019 - 2026)
Prelude Therapeutics (PRLD) posted Assets of $119.6 million for Q1 2026, down 15.34% sequentially from $141.3 million in Q4 2025, and down 15.3% YoY from $141.3 million in Q1 2025.
Prelude Therapeutics (PRLD) Assets (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Assets for 8 years, with the latest figure at $119.6 million in Q1 2026.
- Quarterly Assets fell 15.3% year-over-year to $119.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.6 million (down 15.3% YoY) and the FY2025 annual result came in at $141.3 million, down 19.49% from the prior year.
- Assets eased to $119.6 million in Q1 2026 per PRLD's latest filing, from $141.3 million in the prior quarter.
- Over five years, Assets peaked at $280.7 million in Q1 2022 and troughed at $94.8 million in Q3 2025.
- A 5-year average of $204.3 million and a median of $220.5 million in 2022 frame the typical range for Assets.
- The sharpest annual moves came in 2023 and 2025: Assets grew 25.93% in 2023, then sank 51.95% in 2025.
- Over 5 years, Assets stood at $220.5 million in 2022, then climbed by 25.93% to $277.7 million in 2023, then slumped by 36.79% to $175.5 million in 2024, then fell by 19.49% to $141.3 million in 2025, then retreated by 15.34% to $119.6 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $119.6 million, $141.3 million, and $94.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | 189.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 189.36 Mn |
| Mar 31, 2026 | 119.64 Mn |
| Dec 31, 2025 | 141.32 Mn |
| Sep 30, 2025 | 94.76 Mn |
| Jun 30, 2025 | 114.92 Mn |
| Mar 31, 2025 | 141.26 Mn |
| Dec 31, 2024 | 175.52 Mn |
| Sep 30, 2024 | 197.22 Mn |
| Jun 30, 2024 | 224.29 Mn |
| Mar 31, 2024 | 247.11 Mn |
| Dec 31, 2023 | 277.67 Mn |
| Sep 30, 2023 | 258.51 Mn |
| Jun 30, 2023 | 280.61 Mn |
| Mar 31, 2023 | 198.32 Mn |
| Dec 31, 2022 | 220.50 Mn |
| Sep 30, 2022 | 242.33 Mn |
| Jun 30, 2022 | 259.06 Mn |
| Mar 31, 2022 | 280.67 Mn |
| Dec 31, 2021 | 305.10 Mn |
| Sep 30, 2021 | 331.22 Mn |